Efficacy And Safety of Epaminurad, A Potent Hurat1 Inhibitor, in Patients with Gout: A Randomized, Placebo-Controlled, Dose-Finding Study
A recent study found that epaminurad is well-tolerated and effectively lowers serum uric acid (sUA) levels in patients with gout. Among 169 mostly male participants aged 19–70, those treated with epaminurad showed significantly greater sUA reductions than those on placebo, with response rates of 88.9% (9 mg), 71.8% (6 mg), and 54.1% (3 mg). Adverse events were mostly mild and occurred at similar rates across all groups, with no significant changes in kidney or liver function observed. Full Access: PubMed
Tryptyr Ophthalmic Solution Gets FDA Nod for Dry Eye Disease
The Food and Drug Administration (FDA) has approved Tryptyr® (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease. The approval of Tryptyr was based on data from 2 randomized, double-blind, vehicle-controlled studies. In both trials, patients with dry eye disease were randomly assigned to receive acoltremon ophthalmic solution 0.003% or vehicle eye drop twice daily for 90 days. Full Access: EMPR
Migraine Drug Ubrogepant May Ease Preheadache Symptoms
A recent study suggests that the migraine medication ubrogepant may help relieve preheadache symptoms, also known as prodrome symptoms, which occur before a migraine attack. These symptoms can include fatigue, mood changes, neck pain, sensitivity to light or sound, and difficulty concentrating. Researchers found that individuals who took ubrogepant during a migraine attack not only experienced relief from headache pain but also saw a reduction in these early symptoms. This expands the potential benefit of ubrogepant beyond just treating the headache itself, potentially improving overall quality of life for migraine sufferers. However, further research is needed to confirm these findings and determine how best to use the drug to target prodrome symptoms. Full Access: JAMA
Diphenhydramine: It is Time to Say a Final Goodbye
The article argues that diphenhydramine, a first-generation antihistamine, should no longer be used due to its ineffectiveness compared to newer alternatives and its significant side effects, such as sedation and cognitive impairment. Experts emphasize that second-generation antihistamines like cetirizine and loratadine are safer and more effective. The article urges healthcare providers and regulatory bodies to update guidelines and public messaging to discourage diphenhydramine use, especially in children. Full Access: World Allergy Organization Journal
Gut Microbiome in Adult and Pediatric Patients with Hidradenitis Suppurativa
The study found that both adult and pediatric hidradenitis suppurativa (HS) patients had distinct gut microbial profiles compared to healthy controls, including reduced microbial diversity and increased abundance of pro-inflammatory bacteria. These changes may contribute to systemic inflammation and disease severity. The findings suggest a possible gut-skin axis in HS, opening the door for future therapies targeting the microbiome, such as probiotics, dietary modifications or fecal microbiota transplantation. Full Access: JAMA